Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Gets Downgrade from Wall Street Zen

by · The Markets Daily

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings raised Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. One equities research analyst has rated the stock with a Buy rating. According to MarketBeat.com, the stock has a consensus rating of “Buy”.

Read Our Latest Analysis on Oramed Pharmaceuticals

Oramed Pharmaceuticals Stock Performance

Shares of Oramed Pharmaceuticals stock opened at $3.86 on Friday. The firm has a market cap of $160.58 million, a P/E ratio of 0.94 and a beta of 1.31. The firm’s 50-day simple moving average is $4.46 and its 200-day simple moving average is $4.04. Oramed Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $5.47.

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.52). On average, equities analysts forecast that Oramed Pharmaceuticals will post 1.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Oramed Pharmaceuticals

In other Oramed Pharmaceuticals news, CFO Avraham Gabay sold 20,000 shares of Oramed Pharmaceuticals stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the completion of the transaction, the chief financial officer directly owned 861,076 shares of the company’s stock, valued at approximately $3,883,452.76. This trade represents a 2.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joshua Hexter sold 30,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $4.51, for a total transaction of $135,300.00. Following the completion of the sale, the chief operating officer owned 1,328,130 shares in the company, valued at $5,989,866.30. This represents a 2.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.77% of the company’s stock.

Hedge Funds Weigh In On Oramed Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Hillsdale Investment Management Inc. acquired a new position in Oramed Pharmaceuticals in the first quarter valued at about $331,000. Bank of New York Mellon Corp acquired a new stake in shares of Oramed Pharmaceuticals during the second quarter worth approximately $381,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Oramed Pharmaceuticals during the first quarter worth approximately $63,000. BML Capital Management LLC increased its holdings in shares of Oramed Pharmaceuticals by 2.1% during the third quarter. BML Capital Management LLC now owns 884,392 shares of the biotechnology company’s stock worth $4,130,000 after buying an additional 18,123 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new position in shares of Oramed Pharmaceuticals in the second quarter valued at approximately $61,000. 12.73% of the stock is owned by institutional investors.

Oramed Pharmaceuticals Company Profile

(Get Free Report)

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) is a biopharmaceutical company focused on developing oral formulations of drugs that are typically administered by injection. The company’s proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from degradation in the digestive system and facilitate their absorption through the gastrointestinal tract.

Oramed’s development programs have primarily focused on oral insulin, including its investigational ORMD-0801 product candidate for the treatment of diabetes.

Further Reading